ribociclib

Ligand id: 7383

Name: ribociclib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 91.21
Molecular weight 434.25
XLogP 1.76
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. A-González N, Castrillo A. (2011)
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.
Biochim. Biophys. Acta1812 (8): 982-94. [PMID:21193033]
2. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M et al.. (2010)
The landscape of somatic copy-number alteration across human cancers.
Nature463 (7283): 899-905. [PMID:20164920]
3. Brain CT, Sung MJ, Lago B. (2015)
Pyrrolopyrimidine compounds and their uses.
Patent number: US8962630. Assignee: Novartis Ag. Priority date: 22/08/2008. Publication date: 24/02/2015.
4. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H et al.. (2012)
The requirement for cyclin D function in tumor maintenance.
Cancer Cell22 (4): 438-51. [PMID:23079655]
5. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES. (2012)
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.
Cell Cycle11 (14): 2756-61. [PMID:22767154]
6. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP et al.. (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
N. Engl. J. Med.375 (18): 1738-1748. [PMID:27717303]
7. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaría D, Barbacid M. (2010)
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.
Cancer Cell18 (1): 63-73. [PMID:20609353]
8. Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ et al.. (2013)
Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.
Clin. Cancer Res.19 (22): 6173-82. [PMID:24045179]
9. Sawai CM, Freund J, Oh P, Ndiaye-Lobry D, Bretz JC, Strikoudis A, Genesca L, Trimarchi T, Kelliher MA, Clark M et al.. (2012)
Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.
Cancer Cell22 (4): 452-65. [PMID:23079656]
10. Zhang XH, Cheng Y, Shin JY, Kim JO, Oh JE, Kang JH. (2013)
A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Cancer Biol. Ther.14 (7): 597-605. [PMID:23792647]